Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Chubb
Colorcon
McKinsey
McKesson
Farmers Insurance

Generated: September 15, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,415,053

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,415,053 protect, and when does it expire?

Patent 9,415,053 protects XARELTO and is included in one NDA.

This patent has forty-two patent family members in thirty-four countries.

Summary for Patent: 9,415,053
Title:Solid, orally administrable pharmaceutical composition
Abstract: The present invention relates to a process for the preparation of a solid, orally administrable pharmaceutical composition, comprising 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin- -5-yl}-methyl)-2-thiophenecarboxamide in hydrophilized form, and its use for the prophylaxis and/or treatment of diseases.
Inventor(s): Benke; Klaus (Bergisch Gladbach, DE)
Assignee: Bayer Intellectual Property GmbH (Monheim, DE)
Application Number:14/250,863
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,415,053
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Process; Dosage form; Use;

Drugs Protected by US Patent 9,415,053

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Janssen Pharms XARELTO rivaroxaban TABLET;ORAL 022406-004 Oct 11, 2018 RX Yes No ➤ Sign Up ➤ Sign Up Y REDUCTION OF RISK OF MAJOR CARDIOVASCULAR EVENTS (CV DEATH, MI, AND STROKE) IN CHRONIC CAD OR PAD ➤ Sign Up
Janssen Pharms XARELTO rivaroxaban TABLET;ORAL 022406-001 Jul 1, 2011 RX Yes No ➤ Sign Up ➤ Sign Up Y REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM ➤ Sign Up
Janssen Pharms XARELTO rivaroxaban TABLET;ORAL 022406-001 Jul 1, 2011 RX Yes No ➤ Sign Up ➤ Sign Up Y PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT) ➤ Sign Up
Janssen Pharms XARELTO rivaroxaban TABLET;ORAL 022406-001 Jul 1, 2011 RX Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF PULMONARY EMBOLISM (PE) ➤ Sign Up
Janssen Pharms XARELTO rivaroxaban TABLET;ORAL 022406-001 Jul 1, 2011 RX Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF DEEP VEIN THROMBOSIS (DVT) ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,415,053

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany103 55 461Nov 27, 2003

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Deloitte
McKinsey
Argus Health
Johnson and Johnson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.